Purdue Develops New Strategy for Drug Discovery

Posted: Updated:
Not-for-profit Boilermaker Health Innovations is Purdue's unique strategy to fund researchers up to Phase 1 clinical trials. Not-for-profit Boilermaker Health Innovations is Purdue's unique strategy to fund researchers up to Phase 1 clinical trials.

Research scientists often confront the “valley of death”—the gaping hole that exists between laboratory discoveries and their transformation into new medical treatments and products. And the most lethal factor for most researchers is money. However, Purdue University is blazing an unusual trail to help make ends meet in translational research. Rather than rely on traditional sources, the university has formed a not-for-profit startup to take discoveries from the lab up to Phase 1 human clinical trials.

“We develop a lot of drugs [at Purdue]; there aren’t many academic institutions or cancer centers [in our position]—with 14 of their drugs that are synthesized at their own institution in human clinical trials,” says Purdue Center for Cancer Research Robert Wallace Miller Director Dr. Tim Ratliff. “It’s a real strength here, and we want to improve and speed the process.”

Translating basic research into life-changing treatments is one initiative of Purdue Moves, a program that involves 10 university initiatives designed to enhance research, education and the school’s global impact.

Purdue’s Center for Cancer Research is one of only seven basic science research centers in the country designated by the National Cancer Institute. While Ratliff describes the center as a very efficient entity that can “move things forward in a rapid manner,” the process is still slower than scientists like.

Researchers typically rely on external funding from government sources to help them uncover a discovery, but beyond that, the money often dries up.

“[Government sources] don’t fund drugs from the discovery through all these routine processes you have to go through to get that drug ready to go into clinical trials,” says Ratliff. “You have to take these drugs and develop them, so that we understand the toxicities associated with them, their distribution in the body and other fundamental things before we get into the clinic.”

This is when most scientists encounter the “valley of death,” but Purdue believes it can finance the very expensive process with its newly formed Boilermaker Health Innovations, a not-for-profit startup that represents a unique way to fund the gap. Boilermaker Health believes it will be much speedier than the traditional route of forming for-profit companies that aim to attract investments to reach human clinical trials.

Once Boilermaker Health has funded a scientist through early research, Ratliff says it will spin-off a for-profit company to develop the compound and take it through U.S. Food and Drug Administration approval or sell the drug to a large pharmaceutical company.

“As we develop these drugs from very early stages, we envision those drugs will gain value,” says Ratliff. “While we’re a not-for-profit company, that value will create a fund in Boilermaker Health that will allow us, over time, to become independent and support our cancer research and drug discovery very efficiently through the use of those funds.”

Ratliff acknowledges the unconventional model begs the question of how Boilermaker Health will get its first infusion of cash; he says it will rely on Purdue donors, federal funding agencies and private foundations. The Purdue Research Foundation is also matching each donation, up to a total of $1.3 million.

Additionally, Boilermaker Health is considering an alumni crowdfunding effort. The startup has already received a commitment of $175,000 and is “pushing hard” to collect more donations.

“Earning the match would give us $2.6 million, and that would be sufficient to move our first compound through pre-clinical analyses,” says Ratliff. “Once Boilermaker Health gets the drug through the proof of principle clinical trial, that will enable us to sell the product at a higher value, and that higher value will bring revenue back in. The money that we get back, we re-invest into drug discovery, amplifying our ability to move drugs through the valley of death.”

An external advisory committee is currently evaluating compounds in the Purdue pipeline to select the first for Boilermaker Health to “shepherd.” Leaders are hopeful the university’s unique strengths in drug discovery will also pave an unconventional path to patients.

Ratliff says there’s one question he gets the most about Boilermaker Health Innovations.
Ratliff says an external advisory committee will select the first compound that Boilermaker Health Innovations will “shepherd.”
  • Perspectives

    • How Managers Can Keep Millennials Happy

      There are more than 56 million Millennials either actively participating in the workforce, or searching for a job. With a number like this, it’s no surprise that Millennials have taken the workplace by storm. But what is surprising is how different this generation is from their predecessors. They rely heavily on technology and prefer to communicate via text or email rather than a traditional phone call. Managing millennial employees can be a challenge — how can executives...

    More

Events



  • Most Popular Stories

    • $25M Behavioral Hospital Coming to Central Indiana

      Danville-based Hendricks Regional Health is partnering with US HealthVest to develop a stand-alone behavioral center on the Hendricks campus in Plainfield. Known as the Indianapolis Behavioral Hospital, the facility will provide specialized inpatient and outpatient mental health care to patients of all ages.

    • How Managers Can Keep Millennials Happy

      There are more than 56 million Millennials either actively participating in the workforce, or searching for a job. With a number like this, it’s no surprise that Millennials have taken the workplace by storm. But what is surprising is how different this generation is from their predecessors. They rely heavily on technology and prefer to communicate via text or email rather than a traditional phone call. Managing millennial employees can be a challenge — how can executives...

    • Christel DeHaan to Retire as Christel House CEO

      One of the biggest names in philanthropy in Indiana is announcing her retirement. Christel House International Chief Executive Officer Christel DeHaan will remain board chair, but leave as CEO of the nonprofit she founded 20 years ago. The organization has named former Indianapolis Mayor Bart Peterson to be her successor. CHI's mission is to lift children out of poverty, and it has established learning centers at home in Indianapolis and abroad in Mexico, India, South Africa and...

    • Sturges, CBRE Splitting Up

      A long-time commercial real estate firm in Fort Wayne is going independent. CBRE | Sturges, which became affiliated with the global brand more than 20 years ago, will become Sturges Property Group at the end of this month. The firm was founded in 1975 and bills itself as largest full-service commercial and industrial real estate firm in the region. The shift, Sturges says, will...

    • Endocyte, Novartis Ink $2.1B Merger Agreement

      West Lafayette-based Endocyte Inc. (Nasdaq: ECYT) has announced a merger agreement with a global pharmaceutical giant. The deal with Switzerland-based Novartis AG is valued at $2.1 billion and still requires shareholder approval. Until regulatory and other approvals are met, Endocyte will remain independent. The proposed merger of Endocyte into Novartis is slated to be complete in the first half of next year. Endocyte develops targeted cancer therapies and earlier this...